Rocket Pharmaceuticals, Inc.
RCKT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001281895
In the last 90 days, Rocket Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 7 sales; 180 institutions reported holding it in 13F filings for Q2 2026, worth $341.2M in total; Maverick Capital is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $432.5K in total
- 7
- 13F holdersQ2 2026, −16 vs. previous quarter
- 180
- 13F valueReported value at the end of Q2 2026
- $341.2M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding RCKT, Q2 2026
1 superinvestor reports holding Rocket Pharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Maverick Capital
Lee Ainslie
0.1%
Rocket Pharmaceuticals, Inc.'s share of the portfolio
- Shares
- 3,923,963
- Value
- $13.4M
Latest insider trades
Open-market purchases and sales by Rocket Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 (view filing)8:27 PM ET | Sep 11 | 4 days | Wilson MartinGeneral Counsel | SSale | −75.4K | $3.40 | −$256.5K | −11.2%598.5K after | |
| Aug 20, 2026 (view filing)5:30 PM ET | Aug 18 | 2 days | Wilson MartinGeneral Counsel | SSale | −631 | $3.38 | −$2.13K | −0.1%673.9K after | |
| Aug 20, 2026 (view filing)5:25 PM ET | Aug 18 | 2 days | Shah GauravCEO | SSale | −2.29K | $3.38 | −$7.75K | −0.2%1.06M after | |
| Aug 17, 2026 (view filing)5:52 PM ET | Aug 13 | 4 days | Shah GauravCEO | SSale | −2.84K | $3.38 | −$9.59K | −0.3%1.06M after | |
| Aug 17, 2026 (view filing)5:50 PM ET | Aug 13 | 4 days | Wilson MartinGeneral Counsel | SSale | −3.49K | $3.38 | −$11.8K | −0.5%674.5K after | |
| Aug 13, 2026 (view filing)4:15 PM ET | Aug 11 | 2 days | Stevens Christopher JamesChief Operating Officer | SSale | −36.7K | $3.50 | −$128.3K | −6.8%505.8K after | |
| Aug 13, 2026 (view filing)4:15 PM ET | Aug 11 | 2 days | Chaudhuri SarbaniSee Remarks | SSale | −4.70K | $3.50 | −$16.4K | −1.8%262.8K after | |
| May 26, 2026 (view filing) | May 21 | 5 days | Shah GauravCEO | SSale | −55.7K | $3.09 | −$172.1K | −5.0%1.06M after | |
| May 21, 2026 (view filing) | May 19 | 2 days | Shah GauravCEO | SSale | −2.41K | $3.01 | −$7.25K | −0.2%1.04M after | |
| May 21, 2026 (view filing) | May 19 | 2 days | Wilson MartinGeneral Counsel | SSale | −662 | $3.01 | −$1.99K | −0.1%678.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Rocket Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| RTW Investments, LP | 17,687,772 | $60.5M | 0.52% | 00.0% | Unchanged |
| BlackRock, Inc. | 9,923,962 | $33.9M | 0.00% | +2,089,167+26.7% | Added |
| Vanguard Portfolio Management LLC | 5,810,033 | $19.9M | 0.00% | +1,119,818+23.9% | Added |
| Citigroup Inc | 4,865,551 | $16.6M | 0.01% | −242,157−4.7% | Reduced |
| Marshall Wace, LLP | 4,029,262 | $13.8M | 0.01% | +990,547+32.6% | Added |
| Millennium Management LLC | 4,000,344 | $13.7M | 0.01% | +882,220+28.3% | Added |
| Newtyn Management, LLC | 4,000,000 | $13.7M | 1.71% | +834,100+26.3% | Added |
| Maverick Capital LtdSuperinvestorMaverick Capital | 3,923,963 | $13.4M | 0.12% | +356,591+10.0% | Added |
| Vanguard Capital Management LLC | 3,784,387 | $12.9M | 0.00% | +8,651+0.2% | Added |
| AQR Capital Management LLC | 3,386,162 | $11.6M | 0.00% | +316,232+10.3% | Added |